

Reference Number: FOI202223/450
From: Commercial
Date: 08 December 2022
Subject: Dermatological conditions and drugs used for treatments

- Q1 How many patients were treated in last 4 months by the Dermatology department with each of the following:
- a. Abrocitinib
 - b. Acitretin
 - c. Alitretinoin
 - d. Azathioprine
 - e. Baricitinib
 - f. Ciclosporin
 - g. Dupilumab
 - h. Methotrexate
 - i. Mycophenolate mofetil
 - j. Pimecrolimus
 - k. Tacrolimus ointment
 - l. Tralokinumab
 - m. Upadacitinib
 - n. Phototherapy (UVB or PUVA)
- Q2 Of the patients treated in the last 4 months with any of the products listed in Q1, please provide the number of patients by the following age-groups:
- a. Age 6-11
 - b. Age 12-17
 - c. Age 18 and above
- Q3 If possible, could you please provide the number of patients treated in the last 4 months for atopic dermatitis ONLY with:
- a. Azathioprine
 - b. Ciclosporin
 - c. Methotrexate
 - d. Mycophenolate mofetil
 - e. Phototherapy (UVB or PUVA)
- A1-3 [Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.](#)